



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

Digital Life Line Pte. Ltd. (“DLL”) Signed MOU with Alina Vision for the Trial Deployment of Automated Visual Acuity Test Device in Vietnam

- **The Memorandum of Understanding (“MOU”) is a major milestone in the Group’s commercialisation strategy and marks DLL’s maiden overseas expansion of its Automated Visual Acuity Test Device (“AVAT”)**
- **By 2035, Vietnam will be an aged society that makes it one of the fastest-aging countries in the world where there will be increasing prevalence of age-related eye diseases, according to The World Bank Report ⁽¹⁾**
- **Globally, the Group’s AVAT is one of the first devices that can automate ophthalmology screening, which is essential for eye-care related diseases**
- **DLL recently completed the first trial deployment of the AVAT device in a major public hospital in Singapore**
- **Video demo of AVAT: <https://www.youtube.com/watch?v=GrQSHMd35PM>**

SINGAPORE – 23 April, 2024 — DISA Limited (the “**Company**”) is pleased to share that its subsidiary company, DLL, has announced today on the signing of a MOU with Alina Eye Hospital Social Enterprise Company Limited - Alina Eye Clinic Quang Ninh (“**Alina Vision**”) that involves the trial deployments of AVAT at Alina Vision hospitals in Vietnam.

Incorporated in 2021, DLL is a Singapore-based ISO13485-certified medical technology company that provides digital, AI-powered diagnostic ophthalmology solutions to enable community-based vision screening for early detection and treatment of vision impairment as well as non-invasive diagnostic solutions.

Founded by an international development organisation, The Fred Hollows Foundation, in 2018, Alina Vision, which currently operates two eye hospitals in the underserved Vietnamese ophthalmology market, provides affordable and high-quality eye care services for people across all income levels to combat avoidable blindness and treat eye diseases. Over the past five years, The Fred Hollows Foundation and Rohto Pharmaceutical, a leading eyecare company in Japan, have provided financial support, eye surgery training and clinical assistance to Alina Vision to grow the organisation from inception to more than 80 employees across the two eye hospitals.

In 2013 alone, Alina Vision has completed more than 2,800 cataract surgeries and it has a vision to become a dominant and market leading service provider in the Vietnamese ophthalmology market with a chain of eye hospitals across Vietnam, which can cater to the rising demand for the cataract surgeries that has been undeserved by limited medical resources domestically. Notably, the investment of industry specialist growth capital investor, TVM Capital Healthcare, an emerging markets-focused healthcare private equity firm headquartered in Singapore and Dubai, with offices in Riyadh, Boston, Munich, and Ho Chi Minh City, will provide Alina Vision with access to operational, clinical, training, and management resources, in addition to the equity investment.


Developed by the Department of Ophthalmology at the National University Hospital (“**NUH**”) and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore (“**NUS Medicine**”), AVAT addresses the increasing demand to decentralise the existing care model of conducting eye screening and monitoring of eye diseases. By incorporating automation and digitalisation, AVAT has allowed for more efficient vision testing workflow with minimal costs and manpower resources.

Leveraging on the proprietary optics and intelligent software programming, AVAT recapitulates the standard 6-meter visual acuity test within a tabletop footprint and allows for patients to perform the assessment without the need for trained staff.

The system provides Snellen’s Tumbling E test formats in multiple languages. It also has a pinhole test feature to assess if the “poor vision” is the result of refractive error and if so, it will guide the patients on the subsequent steps to be taken. Results can be easily integrated into electronic medical records, thereby cutting down on human error during data input.

By reducing the need for trained operators, AVAT not only addresses the manpower shortages in the healthcare systems, but also ensures a consistent level of test quality and eliminates human error. Patients have indicated a preference for the AVAT testing format, as it has the potential to significantly reduce wait times and remove the major bottleneck in the clinic workflow.

A portable, tabletop device that allows for accurate, self-testing of visual acuity without the need for trained supervision to address staff shortage and space constraints.



“We are delighted to sign this MOU with Alina Vision and are honoured to have given the opportunity to deploy AVAT outside of Singapore, which is in line with DLL’s commercialisation strategy and to improve accessibility and convenience for accurate vision screening through automation and technology innovation.” **Mr. Eddie Chng, the Managing Director and Chief Executive Officer of the Group said,** “To-date, AVAT has been used on over 2,000 patients in hospitals, schools and community settings. Its performance has been validated to have excellent correlation with standard tests, while outperforming similar devices that claim to reduce the space requirement.”

(1) <https://documents1.worldbank.org/curated/en/544371632385243499/pdf/Vietnam-Adapting-to-an-Aging-Society.pdf>

Issued on behalf of DISA Limited by 8PR Asia Pte. Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technology innovations to enhance outcomes, reduce costs, improve efficiencies within the healthcare and consumer industry.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of product and services that optimises efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.
Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542
Telephone number: +65 6232 3210*